Is it all bad news in the bear market? Not necessarily.
After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest periods of net negative performance for biotech stocks, with the SPDR S&P Biotech ETF XBI extending net losses over a 70-week period.
But things are looking up: the XBI was 7% up in January of this year, and investor sentiment seems to be improving.